{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chlorhydrate de bendamustine : Questions médicales les plus fréquentes",
"headline": "Chlorhydrate de bendamustine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chlorhydrate de bendamustine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-05",
"dateModified": "2026-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chlorhydrate de bendamustine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Benzimidazoles",
"url": "https://questionsmedicales.fr/mesh/D001562",
"about": {
"@type": "MedicalCondition",
"name": "Benzimidazoles",
"code": {
"@type": "MedicalCode",
"code": "D001562",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.103"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chlorhydrate de bendamustine",
"alternateName": "Bendamustine Hydrochloride",
"code": {
"@type": "MedicalCode",
"code": "D000069461",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Richard J Simpson",
"url": "https://questionsmedicales.fr/author/Richard%20J%20Simpson",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of Arizona, Tucson, AZ 85721, USA."
}
},
{
"@type": "Person",
"name": "Emmanuel Katsanis",
"url": "https://questionsmedicales.fr/author/Emmanuel%20Katsanis",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of Arizona, Tucson, AZ 85721, USA."
}
},
{
"@type": "Person",
"name": "Guido Ghilardi",
"url": "https://questionsmedicales.fr/author/Guido%20Ghilardi",
"affiliation": {
"@type": "Organization",
"name": "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Luca Paruzzo",
"url": "https://questionsmedicales.fr/author/Luca%20Paruzzo",
"affiliation": {
"@type": "Organization",
"name": "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Jakub Svoboda",
"url": "https://questionsmedicales.fr/author/Jakub%20Svoboda",
"affiliation": {
"@type": "Organization",
"name": "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Studying the Interaction between Bendamustine and DNA Molecule with SERS Based on AuNPs/ZnCl",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37686321",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241713517"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37199744",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00280-023-04540-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.",
"datePublished": "2024-05-23",
"url": "https://questionsmedicales.fr/article/38827319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.32604/or.2024.046885"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.",
"datePublished": "2023-11-02",
"url": "https://questionsmedicales.fr/article/37916709",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.57264/cer-2023-0073"
}
},
{
"@type": "ScholarlyArticle",
"name": "Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37199050",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.6114"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzimidazoles",
"item": "https://questionsmedicales.fr/mesh/D001562"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chlorhydrate de bendamustine",
"item": "https://questionsmedicales.fr/mesh/D000069461"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chlorhydrate de bendamustine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chlorhydrate de bendamustine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chlorhydrate de bendamustine",
"description": "Comment le chlorhydrate de bendamustine est-il utilisé dans le diagnostic ?\nQuels tests précèdent l'administration de bendamustine ?\nLe bendamustine est-il utilisé pour tous les types de cancers ?\nQuels marqueurs tumoraux sont surveillés avec la bendamustine ?\nLe bendamustine nécessite-t-il une biopsie préalable ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chlorhydrate de bendamustine",
"description": "Quels sont les effets secondaires courants du bendamustine ?\nLe bendamustine provoque-t-il des symptômes allergiques ?\nQuels symptômes indiquent une infection pendant le traitement ?\nLe bendamustine peut-il causer des problèmes gastro-intestinaux ?\nComment gérer la fatigue causée par le bendamustine ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chlorhydrate de bendamustine",
"description": "Comment prévenir les effets secondaires du bendamustine ?\nY a-t-il des précautions à prendre avant le traitement ?\nLe suivi médical est-il important pendant le traitement ?\nComment éviter les infections pendant le traitement ?\nDes vaccinations sont-elles recommandées avant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chlorhydrate de bendamustine",
"description": "Comment le chlorhydrate de bendamustine est-il administré ?\nQuelle est la posologie standard de bendamustine ?\nLe bendamustine peut-il être combiné avec d'autres traitements ?\nQuels sont les critères d'arrêt du traitement par bendamustine ?\nDes soins de soutien sont-ils nécessaires avec le bendamustine ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chlorhydrate de bendamustine",
"description": "Quelles sont les complications possibles du bendamustine ?\nLe bendamustine peut-il causer des problèmes cardiaques ?\nComment gérer une réaction allergique au bendamustine ?\nLe bendamustine augmente-t-il le risque de cancer secondaire ?\nQuels signes indiquent une toxicité du bendamustine ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chlorhydrate de bendamustine",
"description": "Qui est à risque d'effets secondaires du bendamustine ?\nLe statut immunitaire influence-t-il le traitement par bendamustine ?\nLes antécédents médicaux affectent-ils le traitement ?\nLe mode de vie peut-il affecter l'efficacité du bendamustine ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000069461#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le chlorhydrate de bendamustine est-il utilisé dans le diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour le diagnostic, mais pour traiter des cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de bendamustine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie."
}
},
{
"@type": "Question",
"name": "Le bendamustine est-il utilisé pour tous les types de cancers ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est principalement utilisé pour les lymphomes non hodgkiniens et la leucémie lymphoïde chronique."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés avec la bendamustine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CD20 et le CD5 peuvent être surveillés selon le type de cancer."
}
},
{
"@type": "Question",
"name": "Le bendamustine nécessite-t-il une biopsie préalable ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie peut être nécessaire pour confirmer le type de cancer avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants du bendamustine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, et baisse des globules blancs."
}
},
{
"@type": "Question",
"name": "Le bendamustine provoque-t-il des symptômes allergiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques comme éruptions cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection pendant le traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, et douleurs peuvent indiquer une infection due à l'immunosuppression."
}
},
{
"@type": "Question",
"name": "Le bendamustine peut-il causer des problèmes gastro-intestinaux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des diarrhées et des vomissements sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Comment gérer la fatigue causée par le bendamustine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un repos adéquat et une bonne nutrition peuvent aider à gérer la fatigue."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires du bendamustine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à prévenir les nausées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des précautions à prendre avant le traitement ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer le médecin des allergies et des médicaments en cours est essentiel."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il important pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est crucial pour surveiller les effets secondaires et l'efficacité."
}
},
{
"@type": "Question",
"name": "Comment éviter les infections pendant le traitement ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et pratiquer une bonne hygiène peut réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Des vaccinations sont-elles recommandées avant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent être recommandées pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Comment le chlorhydrate de bendamustine est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est administré par voie intraveineuse, généralement en cycles de traitement."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie standard de bendamustine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie selon le type de cancer, mais est souvent de 90 mg/m² en IV."
}
},
{
"@type": "Question",
"name": "Le bendamustine peut-il être combiné avec d'autres traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est souvent combiné avec d'autres agents chimiothérapeutiques pour une efficacité accrue."
}
},
{
"@type": "Question",
"name": "Quels sont les critères d'arrêt du traitement par bendamustine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut être arrêté en cas de toxicité sévère ou de progression de la maladie."
}
},
{
"@type": "Question",
"name": "Des soins de soutien sont-ils nécessaires avec le bendamustine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des soins de soutien comme des transfusions peuvent être nécessaires pour gérer les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du bendamustine ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections, anémie, et réactions allergiques sévères."
}
},
{
"@type": "Question",
"name": "Le bendamustine peut-il causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des problèmes cardiaques sont rares mais peuvent survenir, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique au bendamustine ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de réaction, le traitement doit être arrêté et un médecin consulté immédiatement."
}
},
{
"@type": "Question",
"name": "Le bendamustine augmente-t-il le risque de cancer secondaire ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque accru de cancers secondaires après un traitement prolongé."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une toxicité du bendamustine ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des saignements inhabituels ou des infections fréquentes peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du bendamustine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients âgés et ceux avec des antécédents de maladies hématologiques sont à risque."
}
},
{
"@type": "Question",
"name": "Le statut immunitaire influence-t-il le traitement par bendamustine ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un statut immunitaire affaibli augmente le risque d'infections et de complications."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux affectent-ils le traitement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies cardiaques ou hépatiques peuvent influencer le traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il affecter l'efficacité du bendamustine ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer la tolérance et l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent augmenter les effets secondaires ou diminuer l'efficacité."
}
}
]
}
]
}
Bendamustine (BENDA) is a bifunctional alkylating agent with alkylating and purinergic antitumor activity, which exerts its anticancer effects by direct binding to DNA, but the detailed mechanism of B...
The Stanford V chemotherapy regimen has been used to treat Hodgkin lymphoma (HL) patients since 2002 with excellent cure rates; however, mechlorethamine is no longer available. Bendamustine, a drug st...
Bendamustine plasma concentrations were measured in 118 samples from 20 pediatric patients with low- and intermediate-risk HL who received a single-day dose of 180 mg/m...
Bendamustine concentration vs time demonstrated a trend toward decreasing clearance with increasing age (p = 0.074) and age explained 23% of the inter-individual variability in clearance. The median (...
A single-day dose of 180 mg/m...
Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's l...
A decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and ...
Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction...
Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and p...
Although one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autolo...
R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma....
We describe a case of adenomyosis that reduced in size in a patient with lymphoma on receiving chemotherapy. A 48-year-old woman with worsening left flank pain was diagnosed with follicular lymphoma. ...
Bendamustine (B) with rituximab (R) has become the preferred regimen for patients with indolent lymphoma in Ontario, Canada, compared to R with cyclophosphamide, vincristine, prednisone (CVP) or cyclo...
Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of al...
84 consecutive patients with relapsed or refractory large B-cell lymphoma treated with axi-cel and managed with a uniform toxicity management plan at Stanford University were studied. 27 patients rece...
Best complete response rates were similar (73.7% for FC and 74% for bendamustine, p=0.28) and there was no significant difference in 12-month progression-free survival or overall survival estimates (p...
Bendamustine is a safe and effective alternative lymphodepletion conditioning for axi-cel with lower early hematological toxicity and favorable immune reconstitution....
Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in com...
This protocol details the eligibility criteria, search strategy, study selection, data extraction, and analysis methods for the systematic review. Randomized controlled trials comparing Pola-BR with o...
This systematic review and meta-analysis protocol provides a rigorous framework for evaluating the efficacy of Pola-BR in the treatment of R/R DLBCL. The results will inform clinical decision-making a...
Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard-of-care CAR T-cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preser...